A placebo-controlled trial in which male and female outpatients with an opioid use disorder who express interest in extended-release injectable naltrexone (XR-NTX) are randomized 1:1 to lofexidine/pregabalin or lofexidine/pregabalin placebo for withdrawal management and offered XR-NTX if after completing withdrawal.
A placebo-controlled trial in which male and female outpatients with an opioid use disorder who express interest in extended-release injectable naltrexone (XR-NTX) are randomized 1:1 to lofexidine/pregabalin or lofexidine/pregabalin placebo for withdrawal management and offered XR-NTX if after completing withdrawal. It follows a UG3 study in which 90 inpatients with an OUD who expressed interest in XR-NTX were randomized 2:1 to withdrawal management with lofexidine/pregabalin or lofexidine/placebo pregabalin. Results were that the conditions were equally safe, and that lofexidine/pregabalin was more effective in reducing subjective withdrawal and keeping patients in treatment than lofexidine/placebo pregabalin. The objectives are to study the safety and effectiveness of lofexidine/pregabalin compared to lofexidine/placebo for managing opioid withdrawal and transitioning to XR-NTX in outpatient settings.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
150
lofexidine tablets 0.18mg tabs pregabalin capsules 100mg and 25mg
lofexidine tablets 0.18mg tabs pregabalin capsules 0mg
Mountain Manor Treatment Center
Baltimore, Maryland, United States
NOT_YET_RECRUITINGUniversity of Pennsylvania, Treatment Research Center
Philadelphia, Pennsylvania, United States
RECRUITINGSubjective Opioid Withdrawal Scale (SOWS) scores
Subjective patient reported Opioid Withdrawal measured by the SOWS, (0-30); 0 = no withdrawal/30 = severe withdrawal
Time frame: 10 days per subject, through study completion (N=150)
Study detox completion
Proportion that receives one or more doses of study medication and completed withdrawal (Completing withdrawal management will be defined as having received at least 1 dose of study medication on day 8 and completing the SOWS-Gossop assessment on day 8); and proportion that transition to XR-NTX; adverse events
Time frame: 10 days per subject, through study completion (N=150)
XR-NTX IM injection
proportion that receives 380mg dose of extended-release naltrexone
Time frame: upto 2 days per subject (N=150)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.